CN103233009B - Application of substance capable of reducing expression of zinc finger protein CTCF to preparation of drugs for treating leukemia - Google Patents
Application of substance capable of reducing expression of zinc finger protein CTCF to preparation of drugs for treating leukemia Download PDFInfo
- Publication number
- CN103233009B CN103233009B CN201310153407.3A CN201310153407A CN103233009B CN 103233009 B CN103233009 B CN 103233009B CN 201310153407 A CN201310153407 A CN 201310153407A CN 103233009 B CN103233009 B CN 103233009B
- Authority
- CN
- China
- Prior art keywords
- seq
- ctcf
- zinc finger
- finger protein
- pdsu6
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000032839 leukemia Diseases 0.000 title claims abstract description 52
- 108010014064 CCCTC-Binding Factor Proteins 0.000 title claims abstract description 50
- 102100027671 Transcriptional repressor CTCF Human genes 0.000 title claims abstract description 49
- 230000014509 gene expression Effects 0.000 title claims abstract description 49
- 101710185494 Zinc finger protein Proteins 0.000 title claims abstract description 35
- 102100023597 Zinc finger protein 816 Human genes 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000003814 drug Substances 0.000 title abstract description 11
- 229940079593 drug Drugs 0.000 title abstract description 3
- 239000000126 substance Substances 0.000 title abstract 3
- 230000006907 apoptotic process Effects 0.000 claims abstract description 25
- 108091027967 Small hairpin RNA Proteins 0.000 claims abstract description 21
- 239000004055 small Interfering RNA Substances 0.000 claims abstract description 21
- 108020004414 DNA Proteins 0.000 claims description 43
- 239000000463 material Substances 0.000 claims description 15
- 230000002068 genetic effect Effects 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 11
- 239000012620 biological material Substances 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 244000005700 microbiome Species 0.000 claims description 7
- 230000009261 transgenic effect Effects 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 6
- 101150011616 Ctcf gene Proteins 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 11
- 206010028980 Neoplasm Diseases 0.000 abstract description 9
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 abstract description 3
- 230000006909 anti-apoptosis Effects 0.000 abstract description 3
- 230000000719 anti-leukaemic effect Effects 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 57
- 238000003259 recombinant expression Methods 0.000 description 33
- 239000013604 expression vector Substances 0.000 description 32
- 239000005090 green fluorescent protein Substances 0.000 description 26
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 24
- 239000012634 fragment Substances 0.000 description 21
- 102000053602 DNA Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000001890 transfection Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- 230000029087 digestion Effects 0.000 description 7
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 6
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 6
- 108020004682 Single-Stranded DNA Proteins 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 230000009368 gene silencing by RNA Effects 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 4
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- 108091028664 Ribonucleotide Proteins 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000005547 deoxyribonucleotide Substances 0.000 description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 125000002652 ribonucleotide group Chemical group 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004042 decolorization Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 238000005429 filling process Methods 0.000 description 2
- 210000003811 finger Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 208000022013 kidney Wilms tumor Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 201000008026 nephroblastoma Diseases 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101100491149 Caenorhabditis elegans lem-3 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101000580713 Homo sapiens Probable RNA-binding protein 23 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010062489 Leukaemia recurrent Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100027483 Probable RNA-binding protein 23 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 201000002797 childhood leukemia Diseases 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000019975 dosage compensation by inactivation of X chromosome Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses application of a substance capable of reducing expression of a zinc finger protein CTCF to preparation of drugs for treating leukemia. In particular, the substance reducing expression of the zinc finger protein CTCF can be short hairpin RNA (shRNA) forming a stem-loop structure. The name of the shRNA is shRNA-3. One chain sequence of the stem in the stem-loop structure is SEQ ID No.1 and the other chain sequence of the stem in the stem-loop structure is SEQ ID No.2. The invention proves that the zinc finger protein CTCF is an anti-apoptosis factor and has the function of suppressing cell apoptosis in the ALL (acute lymphoblastic leukemia) cells. Apoptosis of tumor cells-leukemia cells can be promoted by interfering with expression of CTCF. The invention provides a new way for leukemia treatment. The zinc finger protein CTCF is expected to become a potential target for anti-leukemia treatment and has very extensive application prospect in the medical field.
Description
Technical field
The present invention relates to the application of material in preparation treatment leukemia medicament reducing zinc finger protein CTCF and express.
Background technology
Zinc finger protein CTCF also known as CCCTC binding factor, many zinc fingerses albumen of the high conservative be made up of 727 amino acid.It participates in various biological regulatory function, comprises transcriptional activation or suppression, chromatin insulation, Genomic Imprinting and x chromosome inactivation etc.
Research finds that CTCF participates in the generation evolution of multiple human tumor.People have found the tumour-specific sudden change of CTCF zinc fingers in mammary cancer, prostate cancer and the nephroblastoma.This sudden change makes CTCF lose the binding ability with downstream tumour target gene, causes these abnormal gene expressions, causes tumour thus.In addition, CTCF participates in the generation of tumour by epigenetics mechanism.Investigator finds that in the nephroblastoma, colorectal carcinoma and the rectum cancer CTCF binding site exists abnormal methylation phenomenon, and infers that can cause CTCF combined function thus loses, and then induced tumor.Visible CTCF genetics and epigenetics change play a key effect in tumour occurs.
To be hematopoietic stem/progenitor be obstructed and malignant proliferation and the Patients with Hematopoietic Malignancies: A that causes in different differentiation phases generation apoptosis obstacle, differentiation leukemia.This disease is Childhood modal malignant tumour and the modal cause of death.China newly sends out leukemia of children 1.5 ten thousand example left and right every year, and wherein children acute lymphoblastic leukaemia (AcuteLymphoblastic Leukemia, ALL) is modal type, accounts for 75% of leukemia of children.After the eighties in 20th century, due to the combined reinforced treatment of multiple medicines and strong support treatment, the curative ratio of children ALL reaches about 80%, but over nearly 30 years, ALL curative ratio is without significantly improving, and major cause is that leukemic pathogeny is failed to understand so far.In addition, leukemia relapse is also one of important factor.The recurrence rate of current leukemia of children, up to about 15%, has become the most critical factor affecting leukemia children rehabilitation, not only gives infant itself but also brings irremediable grievous injury humorous factor on good terms to family and society.
Therefore, the drug target of the leukemic pathogeny of further investigated, exploration leukemia of children will contribute to the diagnosis and treatment of leukemia of children.
Summary of the invention
A technical problem to be solved by this invention is to provide a kind of short hairpin RNA (shRNA, short hairpin RNA) and the relevant biological material thereof that promote apoptosis of leukemia.
The short hairpin RNA promoting apoptosis of leukemia provided by the present invention, name is called shRNA-3, form stem ring (Stem-loop) structure, in described loop-stem structure, a chain-ordering of stem (Stem) is SEQ ID No.1, and in described loop-stem structure, another chain-ordering of stem is SEQ ID No.2.
Wherein, SEQ ID No.1 is made up of 19 ribonucleotides, and SEQ ID No.2 is made up of 19 ribonucleotides.
Ring (loop) in described short hairpin RNA makes described short hairpin RNA can produce the double-chain small disturbance RNA (siRNA) be made up of the single stranded RNA shown in the single stranded RNA shown in SEQ ID No.1 and SEQ ID No.2 as long as meet.In one embodiment of the invention, the nucleotide sequence of described short hairpin RNA is SEQ ID No.3.
Wherein, SEQ ID No.3 is made up of 47 ribonucleotides, and the 1-19 position of SEQ ID No.3 is identical with SEQ IDNo.1, and the 29-47 position of SEQ ID No.3 is identical with SEQ ID No.2.
The biomaterial that shRNA-3 provided by the present invention is relevant is 1) to 6) in any one:
1) DNA molecular of coding shRNA-3;
2) containing 1) expression cassette of described DNA molecular;
3) containing 1) recombinant vectors of described DNA molecular or containing 2) recombinant vectors of described expression cassette;
4) containing 1) recombinant microorganism of described DNA molecular or containing 2) recombinant microorganism of described expression cassette or containing 3) recombinant microorganism of described recombinant vectors;
5) containing 1) transgenic cell line of described DNA molecular or containing 2) transgenic cell line of described expression cassette or containing claim 3) transgenic cell line of described recombinant vectors;
6) siRNA, the nucleotide sequence of a chain is as SEQ ID No.1, and the nucleotide sequence of another chain is as SEQ ID No.2.
In the biomaterial that above-mentioned shRNA-3 is relevant, 1) DNA molecular of described coding shRNA-3 specifically can be 1) to 3) in the double chain DNA molecule of any one:
1) nucleotide sequence of a chain is SEQ ID No.4, another chain nucleotide sequence be SEQ ID No.5.
2) encoding sequence of described DNA molecular is the 1-47 position of SEQ ID No.4;
3) encoding sequence of described DNA molecular is the 12-58 position of SEQ ID No.5.
Wherein, SEQ ID No.4 is made up of 54 deoxyribonucleotides, and SEQ ID No.5 is made up of 58 deoxyribonucleotides.The 1-47 position of SEQ ID No.4 and the 12-58 position reverse complemental of SEQ ID No.5.
In the biomaterial that above-mentioned shRNA-3 is relevant, 2) described expression cassette, refer to the DNA that can express shRNA-3 in host cell, this DNA not only can comprise the promotor starting shRNA-3 genetic transcription, also can comprise the terminator stopping shRNA-3 genetic transcription.Further, described expression cassette also can comprise enhancer sequence.In one embodiment of the invention, described expression cassette is made up of Pol III terminator (sequence is 5 '-TTTTT-3 ') of the DNA molecular of U6 promotor (its sequence is as shown in SEQ ID No.8), coding shRNA-3 and the DNA molecular of termination coding shRNA-3.3) described recombinant vectors specifically can be the recombinant expression vector pDsU6-sh-3 replacing the expression shRNA-3 that fragment obtains between the Sac I of pDsU6 and Hind III with the DNA molecular of coding shRNA-3, or for replacing the recombinant expression vector pDsU6-GFP-sh-3 of the expression shRNA-3 that fragment obtains between the BamH I of pDsU6-GFP and Hind III with the DNA molecular of coding shRNA-3.PDsU6-GFP uses GFP(green fluorescent protein) gene replaces the recombinant expression vector of the expression GFP that fragment obtains between the Afl II of pDsU6 and BamH I.4) described recombinant microorganism specifically can be bacterium, yeast, algae and fungi.5) transgenic cell line described in does not comprise the reproductive material of animal and plant.
Another technical problem to be solved by this invention is to provide shRNA-3 and relevant biological material is treating and/or preventing the face application of leukemia side.
Any one being applied as in C1 to C4 provided by the present invention:
C1, treat and/or prevent leukemic product (as medicine), its activeconstituents comprises at least one in b1-b3:
b1、shRNA-3;
The DNA molecular of b2, coding shRNA-3;
The biomaterial that b3, above-mentioned shRNA-3 are relevant.
The product (as medicine) of C2, promotion apoptosis of leukemia, its activeconstituents comprises at least one in described b1-b3;
In C3, described b1-b3, at least one material treats and/or prevents the application in leukemic product (as medicine) in preparation;
In C4, described b1-b3, at least one material promotes the application in the product (as medicine) of apoptosis of leukemia in preparation.
In the product of above-mentioned C1 and C2, activeconstituents also can be only at least one in b1-b3.
Another technical problem to be solved by this invention is to provide the purposes of the material reducing zinc finger protein CTCF genetic expression.
The purposes of the material of reduction zinc finger protein CTCF provided by the present invention genetic expression is a1 or a2:
The material of a1, reduction zinc finger protein CTCF genetic expression treats and/or prevents the application in leukemic product (as medicine) in preparation;
The material of a2, reduction zinc finger protein CTCF genetic expression promotes the application in the product (as medicine) of apoptosis of leukemia in preparation.
Wherein, the material of described reduction zinc finger protein CTCF genetic expression is at least one in described b1-b3.
In such use, the aminoacid sequence of described zinc finger protein CTCF is as shown in SEQ ID No.7, and the encoding sequence of described zinc finger protein CTCF gene is as shown in the 445-2628 position of SEQ ID No.6.
Wherein, SEQ ID No.7 is made up of 727 amino-acid residues, and SEQ ID No.6 is made up of 3946 deoxyribonucleotides, and its encoding sequence is 445-2628 position.
Above described leukemia cell can be the cell in body, also can be clone, as people's pre B cell acute lymphoblastic leukemia cell system NALM-6.
Experiment proves, with the mRNA of zinc finger protein CTCF for target spot, RNA is disturbed recombinant expression vector---the recombinant expression vector pDsU6-GFP-sh-3 expressing shRNA-3 proceeds to the leukemia reconstitution cell obtained in the leukemic clone NALM-6 of bone-marrow-derived lymphocyte, its zinc finger protein CTCF expression level is starkly lower than contrast, cell population apoptosis ratio is 28%, is 3.8 times of contrast.The present invention proves that zinc finger protein CTCF is an anti-apoptosis factor, has the effect of inhibited apoptosis in ALL cell, and the expression of interference CTCF can promote that apoptosis occurs tumour cell leukemia cell, and increases the susceptibility of leukemia cell to chemotherapeutics.The present invention is that leukemia treating provides a new approach, and zinc finger protein CTCF is expected to the potential target spot becoming leukemia treatment, has very wide application prospect at medical field.
Accompanying drawing explanation
Fig. 1 is the Western blot result of CTCF in RNA interference restructuring leukemia cell.Wherein, a upper row is with CTCF monoclonal antibody for primary antibodie detects zinc finger protein CTCF, and next row is for primary antibodie detects internal reference GAPDH with GAPDH monoclonal antibody.
Fig. 2 is Annexin V (+)/PI (-) cell proportion that flow cytomery RNA disturbs in restructuring leukemia cell.
Fig. 3 is restructuring leukemia cell early apoptosis ratio bar graph.
Sh-luc, sh-CTCF-1, sh-CTCF-2 and sh-CTCF-3 in Fig. 1-3 represent restructuring leukemia cell NALM-6/pDsU6-GFP-sh-luc, NALM-6/pDsU6-GFP-sh-1, NALM-6/pDsU6-GFP-sh-2 and NALM-6/pDsU6-GFP-sh-3 respectively.
Embodiment
The experimental technique used in following embodiment if no special instructions, is ordinary method.
Material used in following embodiment, reagent etc., if no special instructions, all can obtain from commercial channels.
Experiment in following embodiment all arranges three repetitions, results averaged.
Carrier pDsU6: be documented in following document: Shilai Bao, Tao Lu, Xin Wang, Huyong Zheng, Li-E Wang, Qingyi Wei, Walter N Hittelman and Lei Li.Disruption of theRad9/Rad1/Hus1 (9 – 1 – 1) complex leads to checkpoint signaling and replicationdefects.Oncogene, 2004,23,5586 – 5593.The public can obtain from Beijing Children's Hospital, Capital Medical University, to repeat the application's experiment.
B-ALL clone NALM-6(pre B cell acute lymphoblastic leukemia cell system NALM-6) be documented in following document: Gao Huifang, Zhang Han, Pei Pei, Liu Yi, Li Zhigang, Jiang Jin, Zhang Ruidong, superb, Qi Yu, Zheng Huyong. the expression of splicing factor SF2/ASF in childhood leukemia cells. " Capital University of Medical Sciences's journal ", volume the 03rd phase June the 30th in 2009.The public can obtain from Beijing Children's Hospital, Capital Medical University, to repeat the application's experiment.
The RNA of embodiment 1, zinc finger protein CTCF disturbs recombinant expression vector to build
1, RNA disturbs the selection of target sequence
For the full length cDNA sequence (SEQ ID No.6) of zinc finger protein CTCF encoding gene CTCF, following three segment DNA sequences are selected to be the target sequence that RNA disturbs:
The 809-827 position (i.e. 5 '-TGACTGTACCTGTTGCTAC-3 ') of sh-1:SEQ ID No.6
The 1103-1122 position (i.e. 5 '-ATGTAGATGTGTCTGTCTAC-3 ') of sh-2:SEQ ID No.6
The 1398-1416 position (i.e. 5 '-TACTCGTCCTCACAAGTGC-3 ') of sh-3:SEQ ID No.6
In SEQ ID No.6,445-2628 position is open reading frame, the zinc finger protein CTCF shown in coding SEQ ID No.7.
2, siRNA (siRNA)
Design three kinds of siRNA(siRNA-1, siRNA-2 and the siRNA-3 of three kinds of target sequences for step 1 zinc finger protein CTCF respectively).The target sequence of the target sequence of siRNA-1 to be the target sequence of sh-1, siRNA-2 be sh-2, siRNA-3 is sh-3.
1)siRNA-1
siRNA-1-F:5’-ugacuguaccuguugcuac-3’;
siRNA-1-R:5’-guagcaacagguacaguca-3’;
2)siRNA-2
siRNA-2-F:5’-auguagaugugucugucuac-3’;
siRNA-2-R:5’-guagacagacacaucuacau-3’。
3)siRNA-3
siRNA-3-F:5’-uacucguccucacaagugc-3’(SEQ ID No.1);
siRNA-3-R:5’-gcacuugugaggacgagua-3’(SEQ ID No.2)。
3, short hairpin RNA (shRNA)
According to three kinds of siRNA of step 2, design produces the shRNA-3 of the shRNA-1 of siRNA-1, the shRNA-2 producing siRNA-2, generation siRNA-3.
The sequence of shRNA-1, shRNA-2 and shRNA-3 is following (capitalization is ring sequence, and all the other sequences are stem sequence, forms inverted repeats):
shRNA-1:
5’-ugacuguaccuguugcuacUUCAAGAGAguagcaacagguacaguca-3’;
shRNA-2:
5’-auguagaugugucugucuacUUCAAGAGAguagacagacacaucuacau-3’;
shRNA-3:
5’-uacucguccucacaagugcUUCAAGAGAgcacuugugaggacgagua-3’(SEQ ID No.3)。
Meanwhile, by the shRNA-luc of reticent luciferase gene in contrast:
shRNA-luc:5’-gaagcgcauccaauaccagcUUCAAGAGAgcugguauuggaugcgcuuc-3’
Luciferase (luciferase) be one do not have in front B acute lymphoblastic leukemia cell system NALM-6 cell express albumen, so by with luciferase be the shRNA-luc of target spot in contrast.
4, the Design and synthesis of the DNA molecular of coding siRNA and shRNA
1) be that two single-stranded DNA sequence of double chain DNA molecule (name is called sh-CTCF-1) of expression shRNA-1 of target spot are as follows with sh-1:
CTCF-ssDNA809-1-F:
5’-tgactgtacctgttgctacTTCAAGAGAgtagcaacaggtacagtcacTTTTT
A-3’;
CTCF-ssDNA809-1-R:
5’-
AGCTTAAAAAgtgactgtacctgttgctacTCTCTTGAAgtagcaacaggtacagtca-3’。
2) be that two single-stranded DNA sequence of double chain DNA molecule (name is called sh-CTCF-2) of expression shRNA-2 of target spot are as follows with sh-2:
CTCF-ssDNA1103-2-F:
5’-atgtagatgtgtctgtctacTTCAAGAGAgtagacagacacatctacatcTTTTT
A-3’;
CTCF-ssDNA1103-2-R:
5’-
AGCTTAAAAAgatgtagatgtgtctgtctacTCTCTTGAAgtagacagacacatctacat-3’。
3) be that two single-stranded DNA sequence of double chain DNA molecule (name is called sh-CTCF-3) of expression shRNA-3 of target spot are as follows with sh-3:
CTCF-ssDNA1398-3-F(SEQ ID No.4):
5’-tactcgtcctcacaagtgcTTCAAGAGAgcacttgtgaggacgagtacTTTTT
A-3’;
CTCF-ssDNA1398-3-R(SEQ ID No.5):
5’-
AGCTTAAAAAgtactcgtcctcacaagtgcTCTCTTGAAgcacttgtgaggacgagta-3’。
4) be that two single-stranded DNA sequence of double chain DNA molecule (name is called sh-luc) of expression shRNA-luc of target spot are as follows with luciferase:
lucDNA-F:
5’-gaagcgcatccaataccagcTTCAAGAGAgctggtattggatgcgcttccTTTTTTT
A-3’;
lucDNA-R:
5’-
AGCTTAAAAAAAggaagcgcatccaataccagcTCTCTTGAAgctggtattggatgcgcttc-3’。
Above-mentioned 8 single stranded DNAs are synthesized by Invitrogen company, and underscore part is Hind III cohesive end sequence.
Respectively get 5 μ g(10ng/ μ l) complementary single stranded DNA mixing, 100 DEG C of thermal treatments are after 5 minutes, and annealing at room temperature, obtains double chain DNA molecule, get double chain DNA molecule 5 μ g and carry out phosphatizing treatment, obtain double-stranded DNA reactant sh-CTCF-1, sh-CTCF-2, sh-CTCF-3 and sh-luc.
Wherein, the reaction system (50 μ l) of above-mentioned phosphatizing treatment: double-stranded DNA 5 μ g, 10 × T
4kinase Buffer5 μ l, ATP(10mM) 5 μ l, T
4polynucleotide Kinase(10U/ μ l) 2 μ l, use ddH
2o is supplemented to 50 μ l.
The reaction conditions of above-mentioned phosphatizing treatment: 37 DEG C of water-baths 1 hour, then 100 DEG C of slowly cool to room temperature after 10 minutes, obtain the double-stranded DNA reactant that can be used for construction recombination plasmid.
5, the RNA of zinc finger protein CTCF disturbs recombinant expression vector to build
1) RNA disturbs the structure of recombinant expression vector pDsU6-sh-1, pDsU6-sh-2, pDsU6-sh-3 and pDsU6-sh-luc
Get after carrier pDsU6 first cuts with Sac I enzyme, end-filling process is carried out by T4Polymerase Klenow fragment, the linearized fragment that gel reclaims uses Hind III digestions again, reclaim the skeleton fragment of pDsU6 carrier, the four kinds of double-stranded DNA reactant obtained with step 4 are respectively connected, obtain four kinds of RNA and disturb recombinant expression vector pDsU6-sh-1, pDsU6-sh-2, pDsU6-sh-3, pDsU6-sh-luc, confirm through order-checking, pDsU6-sh-1 is the recombinant expression vector replacing the expression shRNA-1 that fragment obtains between the Sac I of pDsU6 and Hind III with sh-CTCF-1, pDsU6-sh-2 is the recombinant expression vector replacing the expression shRNA-2 that fragment obtains between the Sac I of pDsU6 and Hind III with sh-CTCF-2, pDsU6-sh-3 is the recombinant expression vector replacing the expression shRNA-3 that fragment obtains between the Sac I of pDsU6 and Hind III with sh-CTCF-3, pDsU6-sh-luc is the recombinant expression vector replacing the expression shRNA-luc that fragment obtains between the Sac I of pDsU6 and Hind III with sh-luc.
2) RNA of GFP mark disturbs the acquisition of recombinant expression vector
The construction process of carrier pDsU6-GFP-sh-1, pDsU6-GFP-sh-2, pDsU6-GFP-sh-3, pDsU6-GFP-sh-luc: the RNA getting above-mentioned structure respectively disturbs the recombinant expression vector pDsU6-GFP of recombinant expression vector pDsU6-sh-1, pDsU6-sh-2, pDsU6-sh-3, pDsU6-sh-luc and expression GFP to carry out BamH I and Hind III double digestion, and postdigestive fragment reclaims through gel; The recovery fragment of recombinant expression vector is disturbed to be connected with pDsU6-GFP carrier segments respectively above-mentioned four kinds of RNA, thus obtain RNA interference recombinant vectors pDsU6-GFP-sh-1, pDsU6-GFP-sh-2, pDsU6-GFP-sh-3, pDsU6-GFP-sh-luc of expressing GFP, confirm that pDsU6-GFP-sh-1 is the recombinant expression vector replacing expression GFP and shRNA-1 that fragment obtains between the BamH I of pDsU6-GFP and Hind III with sh-CTCF-1 through order-checking; PDsU6-GFP-sh-2 is the recombinant expression vector replacing expression GFP and shRNA-2 that fragment obtains between the BamH I of pDsU6-GFP and Hind III with sh-CTCF-2; PDsU6-GFP-sh-3 is the recombinant expression vector replacing expression GFP and shRNA-3 that fragment obtains between the BamH I of pDsU6-GFP and Hind III with sh-CTCF-3; PDsU6-GFP-sh-luc is the recombinant expression vector replacing expression GFP and shRNA-luc that fragment obtains between the BamH I of pDsU6-GFP and Hind III with sh-luc.
The construction process of above-mentioned carrier pDsU6-GFP is as follows: with pGFP-N1(purchased from Clontech) be template, at primer P5(5 '-AAGGATCCATTACCGCCATGCATTAG-3 ') and P6(5 '-CCTACGCCTTAAGATACATTG-3 ') guiding under pcr amplification GFP gene, amplified production is through BamH I single endonuclease digestion, and digestion fragment reclaims through gel; Get carrier pDsU6 and carry out Afl II single endonuclease digestion, carry out end-filling process by T4PolymeraseKlenow fragment, after gel reclaims, linearized fragment uses BamH I digestions again, and after digestion, fragment reclaims through gel; Reclaim fragments by these two kinds to connect, obtain carrier pDsU6-GFP, confirm that pDsU6-GFP use GFP(green fluorescent protein through order-checking) recombinant expression vector of the expression GFP that fragment obtains between the Afl II of gene replacement pDsU6 and BamH I.
Embodiment 2, RNAi gene knockout recombinant vectors transfection leukemia cell
1, the cultivation of transfection cell
24h before transfection, with the RPMI-1640 substratum containing 10% foetal calf serum (FBS) at 15ml culture dish, 37 DEG C and 5%CO
2cultivate under condition when B-ALL clone NALM-6 reaches 75% ~ 90% and carry out transfection.
2, transfection
The RNA with GFP label embodiment 1 obtained disturbs recombinant expression vector pDsU6-GFP-sh-1, pDsU6-GFP-sh-2, pDsU6-GFP-sh-3 and carrier pDsU6-GFP-sh-luc(RNAi positive control, for reticent luciferase gene) difference transfection procedure 1 cultured cells, obtain the restructuring leukemia cell NALM-6/pDsU6-GFP-sh-1 disturbing recombinant expression vector pDsU6-GFP-sh-1 containing RNA, the restructuring leukemia cell NALM-6/pDsU6-GFP-sh-2 of recombinant expression vector pDsU6-GFP-sh-2 is disturbed containing RNA, the restructuring leukemia cell NALM-6/pDsU6-GFP-sh-3 of recombinant expression vector pDsU6-GFP-sh-3 and the restructuring leukemia cell NALM-6/pDsU6-GFP-sh-luc containing carrier pDsU6-GFP-sh-luc is disturbed containing RNA.
The concrete grammar of above-mentioned transfection is as follows:
The NALM-6 cell density that counting step 1 is cultivated, gets containing 2 × 10
6the nutrient solution of individual cell, centrifugal 5 minutes of 90g, abandons substratum, adopts 100 μ l electricity to turn liquid (Nucleofector Solution, Lonza) re-suspended cell; Transitional cell suspension is managed to 1.5ml Eppendorf, adds 2 μ g DNA plasmids, refers to that abdomen flicks abundant mixing; Cell/DNA suspension is transferred in electric revolving cup, avoids bubble, cover bowl cover; Electric revolving cup is positioned on the electric swivel base (Nucleofector Device, Lonza) of electroporation, selects electric carryover sequence C-005(to be specially applicable to NALM-6 clone); The RPMI-1640 substratum (10%FBS) getting 2ml preheating mixes with the cell suspension in electric revolving cup, transfers in Tissue Culture Dish, avoids repeatedly aspirating cell suspension; The cell of transfection is placed in incubator, 37 DEG C, 5%CO
2continue in cell culture incubator to cultivate, for detection and the experiment of following embodiment.
Embodiment 3, Western Blot detect the expression of zinc finger protein CTCF in restructuring leukemia cell
Four kinds of restructuring leukemia cell NALM-6/pDsU6-GFP-sh-1 in Example 2 after transfection 72h, NALM-6/pDsU6-GFP-sh-2, NALM-6/pDsU6-GFP-sh-3 and NALM-6/pDsU6-GFP-sh-luc, extract total protein respectively, with GAPDH(glyceraldehyde-3-phosphate dehydrogenase) be internal reference, carry out Western blot detection, the primary antibodie detecting zinc finger protein CTCF is CTCF (molecular weight 83KDa) monoclonal antibody (purchased from Millipore), the primary antibodie detecting internal reference GAPDH is GAPDH(molecular weight 34KDa) monoclonal antibody (purchased from Chinese Shanghai Kang Cheng company), result as shown in Figure 1, result shows: the restructuring leukemia cell NALM-6/pDsU6-GFP-sh-1 disturbing recombinant expression vector pDsU6-GFP-sh-1 containing RNA, disturb the restructuring leukemia cell NALM-6/pDsU6-GFP-sh-2 of recombinant expression vector pDsU6-GFP-sh-2 containing RNA and disturb containing RNA in the restructuring leukemia cell NALM-6/pDsU6-GFP-sh-3 of recombinant expression vector pDsU6-GFP-sh-3, zinc finger protein CTCF expression level is all lower than the restructuring leukemia cell NALM-6/pDsU6-GFP-sh-luc of contrast containing carrier pDsU6-GFP-sh-luc, wherein RNA disturbs recombinant expression vector pDsU6-GFP-sh-1 and RNA to disturb the interference effect of recombinant expression vector pDsU6-GFP-sh-3 better.
The concrete grammar of said extracted total protein is as follows:
90g collects restructuring leukemia cell in centrifugal 5 minutes, washes twice, add 150 ~ 300 μ l RIPA damping fluid [20mM Tris pH7.5,50mM NaCl, 2mM Na with the PBS of precooling
3vO
4, 10mM NaF, 1mM EDTA, 0.1%TritonX-100 and proteinase inhibitor (Roche)], cracking 30min on ice, collecting cell.8V voltage ultrasound 10 seconds × 2 times, 40 seconds, interval; 4 DEG C, the centrifugal 30min of 12000rpm; Draw supernatant, utilize Brandford method to carry out protein quantification; Respectively get 20 μ g total proteins and carry out Western blot detection.
The concrete grammar that Western blot detects is as follows:
1) electrophoresis and transferring film: carry out SDS-PAGE electrophoresis to protein sample to be measured, first electrophoresis 10-30 minute under voltage 80V, enters after separation gel until dye front, voltage is brought up to 160V and continues electrophoresis about 1 hour, until tetrabromophenol sulfonphthalein arrives the bottom of separation gel.After electrophoresis terminates, the protein sample of separation is transferred to nitrocellulose filter (NC film) by electricity consumption transfer method, 400mA(100V), 1 hour (or 350mA(95V), 1.5 hours).
2) closing membrane: wash (Nacl8.0g, 20ml1M Tris-Hcl, Tween-202ml, adding distil water 950ml demarcate pH value to 7.6, then be settled to 1L) NC film 10-15 minute with TBS-T solution.NC film is put into the TBS-T solution containing 5% skim-milk, room temperature closes 1 hour (or 4 DEG C of 12-24 hour).
3) immuning hybridization:
A, primary antibodie are hatched: be diluted in the TBS-T solution containing 5% skim-milk by CTCF monoclonal antibody or GAPDH monoclonal antibody by 1:2000, hatch together with NC film is on decolorization swinging table under room temperature about 1 hour (40 minutes to 1 hour 20 minutes), wash NC film 10 minutes with TBS-T solution 50mL, repeat 3 times.
B, two resists hatches: be diluted in the TBS-T solution containing 5% skim-milk by the goat anti-rabbit igg antibody in conjunction with horseradish peroxidase by 1:3000, hatch together with NC film is on decolorization swinging table under room temperature about 45 minutes (40 minutes to 1 hour 20 minutes), wash NC film 10 minutes with TBS-T solution 50mL, repeat 3 times.
4) ECL reagent colour development: use ECL protein hybridization detection kit (Amersham company of Sweden), carries out NC film color reaction with reference to operation instructions.
The apoptosis of embodiment 4, restructuring leukemia cell detects
Choose good recombinant expression vector pDsU6-GFP-sh-1 and pDsU6-GFP-sh-3 of RNA interference effect and carry out apoptosis detection.Three kinds of restructuring leukemia cells NALM-6/pDsU6-GFP-sh-1, NALM-6/pDsU6-GFP-sh-3 and NALM-6/pDsU6-GFP-sh-luc in Example 2 after transfection 72h, carry out statistical study with flow cytometer to percentage of cerebral apoptosis respectively, result as shown in Figures 2 and 3.
Result shows: the total apoptosis ratio of cell of restructuring leukemia cell NALM-6/pDsU6-GFP-sh-1, NALM-6/pDsU6-GFP-sh-3 and contrast (restructuring leukemia cell NALM-6/pDsU6-GFP-sh-luc) is respectively 7.5%, 28% and 7.4%, illustrate that RNA disturbs recombinant expression vector pDsU6-GFP-sh-3 can effectively reduce/suppress the expression of CTCF in cell, NALM-6/pDsU6-GFP-sh-3 cell population apoptosis ratio is 3.8 times of contrast (restructuring leukemia cell NALM-6/pDsU6-GFP-sh-luc).
The concrete grammar of above-mentioned flow cytometer statistics percentage of cerebral apoptosis is as follows:
300g collects restructuring leukemia cell in centrifugal 5 minutes, washes twice with the PBS of precooling, uses two transfect cell apoptosis detection kit (purchased from American BD company, the BD Pharmingen556547) labeled cell of AnnexinV-APC/PI.Adopt flow cytometer (U.S. company BD, FACSAria II) to collect the cell of 10000 GFP positives, statistical study is carried out to the apoptosis per-cent of cell, observe the Variation Features that leukemia cell ties up to apoptosis aspect.
Embodiment 3,4 proves, zinc finger protein CTCF is an anti-apoptosis factor, in ALL cell, have the effect of inhibited apoptosis, the expression of interference CTCF can promote tumour cell---there is apoptosis in leukemia cell, and increases the susceptibility of leukemia cell to chemotherapeutics.
Claims (8)
1. form the short hairpin RNA of loop-stem structure, it is characterized in that: in described loop-stem structure, a chain-ordering of stem is SEQ ID No.1, in described loop-stem structure, another chain-ordering of stem is SEQ ID No.2.
2. short hairpin RNA according to claim 1, is characterized in that: the nucleotide sequence of described short hairpin RNA is SEQ ID No.3.
3. the DNA molecular of short hairpin RNA described in coding claim 1 or 2.
4., with the relevant biological material of short hairpin RNA described in claim 1 or 2, be 1)-5) in any one:
1) expression cassette containing DNA molecular described in claim 3;
2) recombinant vectors containing DNA molecular described in claim 3 or containing 1) recombinant vectors of described expression cassette;
3) recombinant microorganism containing DNA molecular described in claim 3 or containing 1) recombinant microorganism of described expression cassette or containing 2) recombinant microorganism of described recombinant vectors;
4) transgenic cell line containing DNA molecular described in claim 3 or containing 1) transgenic cell line of described expression cassette or containing claim 2) transgenic cell line of described recombinant vectors;
5) siRNA, the nucleotide sequence of a chain is as SEQ ID No.1, and the nucleotide sequence of another chain is as SEQ ID No.2.
5. treat and/or prevent leukemic product, the activeconstituents of described product comprises at least one in b1-b3:
B1, profit require the short hairpin RNA described in 1 or 2;
B2, DNA molecular according to claim 3;
B3, relevant biological material according to claim 4.
6. promote the product of apoptosis of leukemia, the activeconstituents of described product comprises at least one in b1-b3:
B1, profit require the short hairpin RNA described in 1 or 2;
B2, DNA molecular according to claim 3;
B3, relevant biological material according to claim 4.
7. reduce the purposes of the material of zinc finger protein CTCF genetic expression, described purposes is a1 or a2:
The application that a1, the material reducing zinc finger protein CTCF genetic expression treat and/or prevent in leukemic product in preparation;
The material of a2, reduction zinc finger protein CTCF genetic expression promotes the application in the product of apoptosis of leukemia in preparation; The material of described reduction zinc finger protein CTCF genetic expression is at least one in b1-b3:
B1, profit require the short hairpin RNA described in 1 or 2;
B2, DNA molecular according to claim 3;
B3, relevant biological material according to claim 4.
8. purposes according to claim 7, is characterized in that: the aminoacid sequence of described zinc finger protein CTCF is as shown in SEQ ID No.7, and the encoding sequence of described zinc finger protein CTCF gene is as shown in the 445-2628 position of SEQ ID No.6.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310153407.3A CN103233009B (en) | 2013-04-27 | 2013-04-27 | Application of substance capable of reducing expression of zinc finger protein CTCF to preparation of drugs for treating leukemia |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310153407.3A CN103233009B (en) | 2013-04-27 | 2013-04-27 | Application of substance capable of reducing expression of zinc finger protein CTCF to preparation of drugs for treating leukemia |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103233009A CN103233009A (en) | 2013-08-07 |
CN103233009B true CN103233009B (en) | 2015-04-08 |
Family
ID=48881075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310153407.3A Expired - Fee Related CN103233009B (en) | 2013-04-27 | 2013-04-27 | Application of substance capable of reducing expression of zinc finger protein CTCF to preparation of drugs for treating leukemia |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103233009B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104278026B (en) * | 2013-07-12 | 2017-06-09 | 中国科学院上海生命科学研究院 | The foundation and application of zebra fish candidate stem cell defect model |
CN106913861B (en) * | 2017-02-28 | 2020-02-21 | 上海交通大学医学院附属第九人民医院 | Application of CTCF trap protein in preparation of anti-uveal melanoma drugs |
CN107151708B (en) * | 2017-07-05 | 2020-10-09 | 昆明医科大学第一附属医院 | Application of DNA binding site CTCF-13 of multifunctional transcription regulatory factor CTCF |
CN107119144B (en) * | 2017-07-05 | 2020-10-09 | 昆明医科大学第一附属医院 | Application of DNA binding site CTCF-55 of multifunctional transcription regulatory factor CTCF |
CN112094860A (en) * | 2020-09-09 | 2020-12-18 | 苏州大学 | CTCF-ETO2 blood disease fusion gene and detection primer and application thereof |
-
2013
- 2013-04-27 CN CN201310153407.3A patent/CN103233009B/en not_active Expired - Fee Related
Non-Patent Citations (3)
Title |
---|
A CTCF-binding silencer regulates the imprinted genes AWT1 and WT1-AS and exhibits sequential epigenetic defects during Wilms’ tumourigenesis;Hancock等;《Human Molecular Genetics》;20070108;第16卷(第3期);全文 * |
CTCF Regulates Growth and Erythroid Differentiation of Human Myeloid Leukemia Cells;Torrano等;《the Journal of Biological Chemistry》;20050606;第280卷(第30期);摘要部分 * |
CTCF/pEGFP-N1 过表达载体及CTCF-shRNA 真核表达载体的构建及鉴定;刘秋英等;《中国科技论文在线数据库》;20120924;第2页第1.2.3节 * |
Also Published As
Publication number | Publication date |
---|---|
CN103233009A (en) | 2013-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xie et al. | LncRNA MALAT1 inhibits apoptosis and promotes invasion by antagonizing miR-125b in bladder cancer cells | |
Liang et al. | Systematic analyses reveal long non-coding RNA (PTAF)-mediated promotion of EMT and invasion-metastasis in serous ovarian cancer | |
JP5480132B2 (en) | Oncogenic ALL-1 fusion protein for targeting DROSHA-mediated microRNA processing | |
CN103233009B (en) | Application of substance capable of reducing expression of zinc finger protein CTCF to preparation of drugs for treating leukemia | |
Hu et al. | Antisense oligonucleotide against miR-21 inhibits migration and induces apoptosis in leukemic K562 cells | |
Chen et al. | Long noncoding RNA CNALPTC1 promotes cell proliferation and migration of papillary thyroid cancer via sponging miR-30 family | |
CN104975023A (en) | Human cervical carcinoma metastasis relevant new long chain non-coding RNA sequence, separation method and uses thereof | |
CN105861551B (en) | The carrier and its construction method of Combined expression microRNAs inhibition Cells Proliferation of Human Breast Cancer and application | |
Yu et al. | Chemosensitization of solid tumors by inhibition of Bcl-xL expression using DNAzyme | |
CN107693535A (en) | A kind of microRNA application | |
CN101457224A (en) | MiR-21 antisense digonucleotides and use thereof | |
Wang et al. | Interaction of microRNA-21/145 and Smad3 domain-specific phosphorylation in hepatocellular carcinoma | |
CN102747083B (en) | Application of splicing factor oncoprotein SF2/ASF in preparation of medicines used for treating leukemia | |
CN101096670B (en) | SiRNA interfering human a-fetoprotein gene and recombinant adenovirus | |
CN107523566A (en) | A kind of targeted inhibition agent of MCM3AP AS1 genes and application thereof | |
CN101445534A (en) | Use of high efficiency siRNA for preparing tumor migration inhibition drug | |
CN101987197A (en) | Method and reagent for inhibiting invasiveness of cancer cells | |
Zhao et al. | MicroRNA targeting microtubule cross-linked protein (MACF1) would suppress the invasion and metastasis of malignant tumor | |
CN101353655B (en) | siRNA inhibiting expression of vascular endothelial growth factor receptor genes and use thereof | |
CN100386435C (en) | Small interfering RNA for suppressing multiple effect growth factor expression and its uses | |
CN109694868A (en) | It is a kind of inhibit sFRP1 gene expression siRNA and its application | |
CN114958856B (en) | Application of long-chain non-coding RNA CYP1B1-AS1 AS breast cancer biomarker and treatment target | |
CN104164434A (en) | siRNA molecule interfering with Survivin gene expression and application thereof | |
CN102041270B (en) | Construction and screening of siRNAs (small interfering RANs) expression vectors of gastric cancer targeted DEC1 (differentiated embryo-chondrocyte expressed gene 1) and application thereof | |
CN104491880A (en) | Application of Micro RNA-141 as inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150408 Termination date: 20200427 |
|
CF01 | Termination of patent right due to non-payment of annual fee |